Patient-centric dose equivalency pilot study of incobotulinumtoxin a (xeomin) vs. abobotulinumtoxin a (dysport) in the treatment of glabellar frown lines

Abstract

Aim: Incobotulinumtoxin A (xeomin) has been proposed as an alternative to abobotulinumtoxin A (dysport) and onabotulinumtoxin A (Botox) in the treatment of glabellar frown lines. A recent study is comparing abobotulinumtoxin A and onabotulinumtoxin A revealed equivalent efficacy with a dose conversion ratio of 2.5:1. We sought to establish effectiveness and dosing equivalency of incobotulinumtoxin A vs. abobotulinumtoxin A.

Methods: Inclusion criteria for this pilot study included patients of a single surgeon (LAC) who had previously received a constant dose of abobotulinumtoxin A over at least four consecutive treatment sessions for the previous 12 months to achieve an 85-90% elimination of dynamic glabellar frown lines. The primary outcome sought dose comparison between established maintenance abobotulinumtoxin A dosing and incobotulinumtoxin A first-time dosing. A 2:1 conversion (abobotulinumtoxin A: incobotulinumtoxin A) was chosen in most patients. Secondary outcomes were patient-reported onset of effect, physician-assessed effect at 10-12 weeks, pain associated with administration, and patient perceived need for re-treatment at 2 weeks.

Results: A total of 32 subjects were included. The mean dose of incobotulinumtoxin A was 17.1 units (± 6.1, the median dose 20 units). The mean dose of abobotulinumtoxin A was 27.6 (± 11.7, the median dose 27.5 units). The mean difference in treatment units was -10.5 (95% confidence interval, P < 0.001). Among 30 patients who reported effect onset, the median was 8.5 days, with a range of 1-14. At 10-12 weeks, muscle paralysis was assessed to be 69.2% (± 27.3), vs. 90.3% (± 1.8) with abobotulinumtoxin A (P < 0.001). The majority of patients rated pain of administration as equal or greater to that of abobotulinumtoxin A (63% and 22%, respectively). Three patients (9%) required re-treatment at 2 weeks with abobotulinumtoxin A due to lack of effective treatment with incobotulinumtoxin A. Abobotulinumtoxin A re-treatment was chosen by the patient.

Conclusion: We found incobotulinumtoxin A at 17.1 (± 6.1) units to be less effective than abobotulinumtoxin A at 27.6 (± 11.7) units in the treatment of glabellar frown lines at 10-12 weeks postadministration. Dosing was less predictable than dosing associated with abobotulinumtoxin A treatment. Larger, randomized controlled trials are indicated to further delineate these differences and to clarify whether this difference from previously published incobotulinumtoxin A dosing may have been due to the small sample size.

Keywords

Abobotulinumtoxin A / glabellar frown lines / incobotulinumtoxin A / rhytids

References

[1] Cosmetic surgery national data bank: statistics 2012..Aesthet Surg J2013;33:S1-21

[2] Klein AW,Fagien S.Comparisons among botulinum toxins: An evidence-based review..Plast Reconstr Surg2008;121:e413-22

[3] Dressler D,Meyer-Rogge E,Bigalke H.Antibody-induced failure of botulinum toxin a therapy in cosmetic indications..Dermatol Surg2010;36 Suppl 4:2182-7

[4] Ipsen Biopharmaceuticals, Medicis Aesthetics. Medication Guide Dysport (dis-port) (abobotulinumtoxinA) Injection. 2012. Availabe from: http://www.pi.medicis.us/medication_guide/dysport.pdf. [Last accessed on 2014 Jul 10].

[5] Merz Pharmaceuticals, Merz Aesthetics. Medication Guide Xeomin (zeo-min) (incobotulinumtoxinA) for Injection, for Intramuscular Use. 2011. Available from: http://www.xeominaesthetic.com/ EM00674-XEOMIN-Medication-Guide.pdf. [Last accessed on 2014 Jul 10].

[6] Matarasso A.Botulinum neurotoxin type A-ABO (Dysport): clinical indications and practice guide..Aesthet Surg J2009;29:S72-9

[7] Flynn TC.Botulinum toxin: examining duration of effect in facial aesthetic applications..Am J Clin Dermatol2010;11:183-99

[8] Michaels BM,Ryb GE,Rubin A.Prospective randomized comparison of onabotulinumtoxinA (Botox) and abobotulinumtoxinA (Dysport) in the treatment of forehead, glabellar, and periorbital wrinkles..Aesthet Surg J2012;32:96-102

[9] Freeman SR.New neurotoxins on the horizon..Aesthet Surg J2008;28:325-30

[10] Sattler G,Grablowitz D,Bee EK,Flynn TC.Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines..Dermatol Surg2010;36 Suppl 4:2146-54

[11] Lorenc ZP,Fagien S,Nestor MS,Sykes JM.IncobotulinumtoxinA (Xeomin): background, mechanism of action, and manufacturing..Aesthet Surg J2013;33:S18-22

[12] Fagien S.A comprehensive review of patient-reported satisfaction with botulinum toxin type a for aesthetic procedures..Plast Reconstr Surg2008;122:1915-25

[13] Kane MA,Rohrich RJ,Monheit GD,Reloxin Investigational Group..Evaluation of variable-dose treatment with a new U.S. Botulinum Toxin Type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study..Plast Reconstr Surg2009;124:1619-29

[14] Baumann L,Kane MA.An analysis of efficacy data from four phase III studies of botulinum neurotoxin type A-ABO for the treatment of glabellar lines..Aesthet Surg J2009;29:S57-65

[15] Rubin M,Maas C.An analysis of safety data from five phase III clinical trials on the use of botulinum neurotoxin type A-ABO for the treatment of glabellar lines..Aesthet Surg J2009;29:S50-6

[16] Carruthers JD,Menter MA,Eadie N.Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines..Plast Reconstr Surg2003;112:1089-98

[17] Lowe PL,Lowe NJ.A comparison of two botulinum type a toxin preparations for the treatment of glabellar lines: double-blind, randomized, pilot study..Dermatol Surg2005;31:1651-4

[18] Prager W.Differential characteristics of incobotulinumtoxin A and its use in the management of glabellar frown lines..Clin Pharmacol2013;5:39-52 PMCID:PMC3600936

[19] Carruthers A.Commentary: long-term treatment of glabellar rhytides using onabotulinumtoxina..Dermatol Surg2011;37:929-30

[20] Prager W,Taufig AZ,Kühne U,Kuhr LP,Philipp-Dormston WG,Roth C,Ulmann C.Botulinum toxin type A treatment to the upper face: retrospective analysis of daily practice..Clin Cosmet Investig Dermatol2012;5:53-8 PMCID:PMC3393118

[21] Moy R,Monheit G,Reloxin Investigational Group..Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines..Arch Facial Plast Surg2009;11:77-83

[22] Brandt F,Baumann L.Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety..Dermatol Surg2009;35:1893-901